BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

...Karyopharm Therapeutics Inc. has XPO1 inhibitors in preclinical-Phase III testing for multiple cancer indications, and CanBas Co. Ltd....
...Institute of MIT and Harvard, Cambridge, Mass. Buck Institute for Research on Aging, Novato, Calif. CanBas Co. Ltd....
BioCentury | Feb 11, 2013
Finance

Bubbling up in Japan

...52-wk range 2012 2013YTD 2/8 mcap AnGes MG Inc. (Tokyo:4563) ¥75,000 ¥24,530-¥101,300 21% 40% $108.4 CanBas Co. Ltd....
BioCentury | Jun 11, 2012
Clinical News

CBP501: Preliminary Phase II data

...Best ORR was 32% in patients receiving CBP501 plus chemotherapy vs. 14% for chemotherapy alone. CanBas...
...PFS, OS and ORR endpoints. The most common adverse events were grade 1/2 infusion reactions. CanBas...
...combination with cisplatin and pemetrexed. Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) markets Alimta pemetrexed. CanBas Co. Ltd....
BioCentury | Jun 5, 2012
Clinical News

CanBas' CBP501 meets mesothelioma endpoint

...response rate was 32% in patients receiving CBP501 plus chemotherapy vs. 14% for chemotherapy alone. CanBas...
...the median PFS, OS and ORR endpoints. CanBas was off Y14 to Y474 on Monday. CanBas...
BioCentury | Jan 16, 2012
Clinical News

CBP501 regulatory update

...Orphan Drug designation for CanBas' CBP501 to treat mesothelioma in combination with cisplatin and pemetrexed. CanBas...
...cell cycle G2 checkpoint blocker. Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) markets Alimta pemetrexed. CanBas Co. Ltd....
BioCentury | Nov 7, 2011
Clinical News

CBP501: Completed Phase II enrollment

...vs. pemetrexed and cisplatin alone. Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) markets Alimta pemetrexed. CanBas Co. Ltd....
BioCentury | Nov 7, 2011
Clinical News

CBP501: Completed Phase II enrollment

...vs. pemetrexed and cisplatin alone. Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) markets Alimta pemetrexed. CanBas Co. Ltd....
BioCentury | Jul 18, 2011
Finance

RaQualia scores

...11, 2006) . Recent Japanese IPOs for regenerative medicine play CellSeed Inc. (Tokyo:7776), cancer company CanBas Co. Ltd....
...¥2.3 billion ($24.8 million) offering last year was the largest of the group. In 2009, CanBas...
BioCentury | Jan 4, 2010
Finance

IPO performance

...NASDAQ:OMER) 10/7/09 $68.2 $212.9 $149.5 -30% Talecris Biotherapeutics Inc. (NASDAQ:TLCR) 9/30/09 $550.0 $2,275.9 $2,667.9 17% CanBas Co. Ltd....
BioCentury | Oct 19, 2009
Finance

Ebb & Flow

...company to price an IPO in a month, following in the footsteps of cancer company CanBas Co. Ltd....
...for glaucoma. Both are expected to begin Phase III testing in 2011. In addition to CanBas...
Items per page:
1 - 10 of 20
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

...Karyopharm Therapeutics Inc. has XPO1 inhibitors in preclinical-Phase III testing for multiple cancer indications, and CanBas Co. Ltd....
...Institute of MIT and Harvard, Cambridge, Mass. Buck Institute for Research on Aging, Novato, Calif. CanBas Co. Ltd....
BioCentury | Feb 11, 2013
Finance

Bubbling up in Japan

...52-wk range 2012 2013YTD 2/8 mcap AnGes MG Inc. (Tokyo:4563) ¥75,000 ¥24,530-¥101,300 21% 40% $108.4 CanBas Co. Ltd....
BioCentury | Jun 11, 2012
Clinical News

CBP501: Preliminary Phase II data

...Best ORR was 32% in patients receiving CBP501 plus chemotherapy vs. 14% for chemotherapy alone. CanBas...
...PFS, OS and ORR endpoints. The most common adverse events were grade 1/2 infusion reactions. CanBas...
...combination with cisplatin and pemetrexed. Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) markets Alimta pemetrexed. CanBas Co. Ltd....
BioCentury | Jun 5, 2012
Clinical News

CanBas' CBP501 meets mesothelioma endpoint

...response rate was 32% in patients receiving CBP501 plus chemotherapy vs. 14% for chemotherapy alone. CanBas...
...the median PFS, OS and ORR endpoints. CanBas was off Y14 to Y474 on Monday. CanBas...
BioCentury | Jan 16, 2012
Clinical News

CBP501 regulatory update

...Orphan Drug designation for CanBas' CBP501 to treat mesothelioma in combination with cisplatin and pemetrexed. CanBas...
...cell cycle G2 checkpoint blocker. Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) markets Alimta pemetrexed. CanBas Co. Ltd....
BioCentury | Nov 7, 2011
Clinical News

CBP501: Completed Phase II enrollment

...vs. pemetrexed and cisplatin alone. Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) markets Alimta pemetrexed. CanBas Co. Ltd....
BioCentury | Nov 7, 2011
Clinical News

CBP501: Completed Phase II enrollment

...vs. pemetrexed and cisplatin alone. Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) markets Alimta pemetrexed. CanBas Co. Ltd....
BioCentury | Jul 18, 2011
Finance

RaQualia scores

...11, 2006) . Recent Japanese IPOs for regenerative medicine play CellSeed Inc. (Tokyo:7776), cancer company CanBas Co. Ltd....
...¥2.3 billion ($24.8 million) offering last year was the largest of the group. In 2009, CanBas...
BioCentury | Jan 4, 2010
Finance

IPO performance

...NASDAQ:OMER) 10/7/09 $68.2 $212.9 $149.5 -30% Talecris Biotherapeutics Inc. (NASDAQ:TLCR) 9/30/09 $550.0 $2,275.9 $2,667.9 17% CanBas Co. Ltd....
BioCentury | Oct 19, 2009
Finance

Ebb & Flow

...company to price an IPO in a month, following in the footsteps of cancer company CanBas Co. Ltd....
...for glaucoma. Both are expected to begin Phase III testing in 2011. In addition to CanBas...
Items per page:
1 - 10 of 20